CVS Health Corp. (CVS) announced on Monday the initiation of cash tender offers for all outstanding 4.100% Senior Notes due 2025, along with several other note series issued by Aetna Inc., its wholly owned subsidiary. This strategic decision aims to reduce the company’s debt and enhance its financial foundation.
The total purchase price for these notes, not including accrued interest, will be capped at $2 billion. To fund this buyback, the company plans to utilize proceeds from an upcoming issuance of subordinated debt securities.
Currently, CVS Health's stock price is experiencing a decline of 1.47%, trading at $58.97 on the New York Stock Exchange.
